{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:07:47Z","timestamp":1779246467295,"version":"3.51.4"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803175"],"award-info":[{"award-number":["81803175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004761","name":"Hainan Province Natural Science Foundation","doi-asserted-by":"publisher","award":["822MS211"],"award-info":[{"award-number":["822MS211"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004761","name":"Hainan Province Natural Science Foundation","doi-asserted-by":"publisher","award":["823MS176"],"award-info":[{"award-number":["823MS176"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119321","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:07:36Z","timestamp":1776172056000},"page":"119321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["IL-13R\u03b12 in liver cancer: Endothelial target for precision therapy"],"prefix":"10.1016","volume":"198","author":[{"given":"Qiumeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yani","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junnan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guandou","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-5858","authenticated-orcid":false,"given":"Xin","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119321_bib1","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib2","article-title":"Improving surgical treatments for hepatocellular carcinoma","author":"Malik","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119321_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4174\/astr.2025.109.3.123","article-title":"Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association","volume":"109","author":"Park","year":"2025","journal-title":"Ann. Surg. Treat. Res."},{"key":"10.1016\/j.biopha.2026.119321_bib4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119321_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105065","article-title":"Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma","volume":"10","author":"Finn","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2026.119321_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.biopha.2026.119321_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119321_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2026.119321_bib10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119321_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41568-023-00591-5","article-title":"Understanding tumour endothelial cell heterogeneity and function from single-cell omics","volume":"23","author":"Zeng","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119321_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119321_bib14","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41419-023-06119-x","article-title":"Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications","volume":"14","author":"Fang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2026.119321_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41388-024-03228-5","article-title":"The influence of endothelial metabolic reprogramming on the tumor microenvironment","volume":"44","author":"Kane","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119321_bib16","doi-asserted-by":"crossref","first-page":"a006536","DOI":"10.1101\/cshperspect.a006536","article-title":"Tumor endothelial cells","volume":"2","author":"Dudley","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.biopha.2026.119321_bib17","article-title":"Interleukin 13 receptor alpha 2 (IL13R\u03b12): Expression, signaling pathways and therapeutic applications in cancer","volume":"2022","author":"Ja\u00e9n","year":"1877","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119321_bib18","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.4049\/jimmunol.161.5.2317","article-title":"The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1","volume":"161","author":"Donaldson","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119321_bib19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1084\/jem.20020906","article-title":"Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2.","volume":"197","author":"Wood","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2026.119321_bib20","article-title":"Tralokinumab Effectively Disrupts the IL-13\/IL-13R\u03b11\/IL-4R\u03b1 Signaling Complex but Not the IL-13\/IL-13R\u03b12 Complex","volume":"3","author":"Tollenaere","year":"2023","journal-title":"JID Innovations Skin Sci. Mol. Population Health"},{"key":"10.1016\/j.biopha.2026.119321_bib21","first-page":"1103","article-title":"IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells","volume":"62","author":"Rahaman","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119321_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.str.2010.01.003","article-title":"Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2.","volume":"18","author":"Lupardus","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.biopha.2026.119321_bib23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1084\/jem.20020903","article-title":"Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response","volume":"197","author":"Chiaramonte","year":"2003","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.biopha.2026.119321_bib24","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1172\/JCI31546","article-title":"IL-13Ralpha2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice","volume":"117","author":"Wilson","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2026.119321_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878365","article-title":"Recent Advances in IL-13R\u03b12-Directed Cancer Immunotherapy","volume":"13","author":"Knudson","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119321_bib26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11060-024-04909-7","article-title":"Clinical progress in the development of CAR T cells to treat malignant glioma","volume":"171","author":"Grewal","year":"2025","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.biopha.2026.119321_bib27","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119321_bib28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00432-009-0724-z","article-title":"Expression of IL-13Ralpha2 in liver cancer cells and its effect on targeted therapy of liver cancer","volume":"136","author":"Hou","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/2211-5463.12774","article-title":"Silencing of IL13RA2 promotes partial epithelial-mesenchymal transition in hepatocellular carcinoma via ERK signaling pathway activation","volume":"10","author":"Wang","year":"2020","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.biopha.2026.119321_bib30","article-title":"HCCDB v2.0: Decompose Expression Variations by Single-cell RNA-seq and Spatial Transcriptomics in HCC.","volume":"22","author":"Jiang","year":"2024","journal-title":"Genom. Proteom. Bioinforma."},{"key":"10.1016\/j.biopha.2026.119321_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cyto.2015.05.008","article-title":"The differential expression of IL-4 and IL-13 and its impact on type-2 immunity","volume":"75","author":"Bao","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2026.119321_bib32","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119321_bib33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12929-025-01142-w","article-title":"Decoding innate lymphoid cells and innate-like lymphocytes in asthma: pathways to mechanisms and therapies","volume":"32","author":"Thio","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2026.119321_bib34","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jaci.2025.01.035","article-title":"Real-life observation of wildfire smoke-impaired COVID-19 vaccine immunity","volume":"155","author":"Sanghar","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2026.119321_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaci.2024.11.003","article-title":"Update on type 2 immunity","volume":"155","author":"Gorska","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2026.119321_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41423-025-01261-2","article-title":"Type 2 immunity in allergic diseases","volume":"22","author":"Ogulur","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.biopha.2026.119321_bib37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imm.13943","article-title":"The Roles of T Cells in the Development of Metabolic Dysfunction-Associated Steatohepatitis","volume":"176","author":"Ge","year":"2025","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2026.119321_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1599748","article-title":"Mechanisms of innate immune cells in Metabolic dysfunction-associated steatotic liver disease","volume":"16","author":"Yao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119321_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105344","article-title":"Polymeric immunoglobulin receptor promotes Th2 immune response in the liver by increasing cholangiocytes derived IL-33: a diagnostic and therapeutic biomarker of biliary atresia","volume":"108","author":"Li","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2026.119321_bib40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-pharmtox-020524-012013","article-title":"Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy","volume":"65","author":"Gilgenkrantz","year":"2025","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2026.119321_bib41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/82771","article-title":"NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway","volume":"1","author":"Terabe","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2026.119321_bib42","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","volume":"22","author":"Seyhan","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.biopha.2026.119321_bib43","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.dld.2021.07.006","article-title":"Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma","volume":"54","author":"Li","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.biopha.2026.119321_bib44","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-020-00411-3","article-title":"Role of liver sinusoidal endothelial cells in liver diseases","volume":"18","author":"Gracia-Sancho","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119321_bib45","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: Physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119321_bib46","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/HEP.0000000000000207","article-title":"The evolving role of liver sinusoidal endothelial cells in liver health and disease","volume":"78","author":"McConnell","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119321_bib47","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/carcin\/9.9.1617","article-title":"Glutathione S-transferase isoenzymes and glutathione peroxidase activity in normal and tumour samples from human lung","volume":"9","author":"Carmichael","year":"1988","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2026.119321_bib48","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/hep.27376","article-title":"Liver sinusoidal endothelial cells in hepatic fibrosis","volume":"61","author":"DeLeve","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119321_bib49","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jcmgh.2020.12.007","article-title":"Single-Cell Transcriptomics Reveals Zone-Specific Alterations of Liver Sinusoidal Endothelial Cells in Cirrhosis","volume":"11","author":"Su","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119321_bib50","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2020.08.040","article-title":"Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma","volume":"183","author":"Sharma","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119321_bib51","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1158\/1078-0432.CCR-08-2780","article-title":"Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells","volume":"15","author":"Xiong","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119321_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115013","article-title":"The role of tumor-associated endothelial cells in malignant progression and immune evasion of liver cancer","volume":"161","author":"Pu","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2026.119321_bib53","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1111\/cas.70179","article-title":"Tumor Endothelial Cells Induce M2 Macrophage Polarization via IL-4, Enhancing Tumor Growth in Hepatocellular Carcinoma","volume":"116","author":"Matoba","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2026.119321_bib54","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2024.09.044","article-title":"CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma","volume":"82","author":"Lu","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119321_bib55","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jare.2024.12.008","article-title":"CD34+CLDN5+ tumor associated senescent endothelial cells through IGF2-IGF2R signaling increased cholangiocellular phenotype in hepatocellular carcinoma","volume":"76","author":"Zhu","year":"2025","journal-title":"J. Adv. Res"},{"key":"10.1016\/j.biopha.2026.119321_bib56","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.4049\/jimmunol.176.12.7456","article-title":"IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets","volume":"176","author":"Andrews","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119321_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119321_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh2169","article-title":"A single-cell type transcriptomics map of human tissues","volume":"7","author":"Karlsson","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2026.119321_bib59","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1038\/s41467-018-06318-7","article-title":"Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations","volume":"9","author":"MacParland","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119321_bib60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","article-title":"Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches","volume":"185","author":"Guilliams","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119321_bib61","doi-asserted-by":"crossref","first-page":"451","DOI":"10.24272\/j.issn.2095-8137.2023.031","article-title":"Cell atlas of CCl 4-induced progressive liver fibrosis reveals stage-specific responses","volume":"44","author":"Guo","year":"2023","journal-title":"Zool. Res."},{"key":"10.1016\/j.biopha.2026.119321_bib62","doi-asserted-by":"crossref","first-page":"eadz3223","DOI":"10.1126\/sciadv.adz3223","article-title":"Decoding the CHI3L1\/IL-13R\u03b12 signaling nexus in MASH-fibrosis pathogenesis","volume":"11","author":"Zheng","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2026.119321_bib63","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1053\/j.gastro.2011.08.008","article-title":"Accelerated and progressive and lethal liver fibrosis in mice that lack interleukin (IL)-10, IL-12p40, and IL-13R\u03b12","volume":"141","author":"Mentink-Kane","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2026.119321_bib64","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hep.22934","article-title":"The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis","volume":"50","author":"Weng","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119321_bib65","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119321_bib66","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1073\/pnas.0305064101","article-title":"IL-13 receptor alpha 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis","volume":"101","author":"Mentink-Kane","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2026.119321_bib67","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119321_bib68","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver","volume":"53","author":"Remmerie","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2026.119321_bib69","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41575-018-0020-y","article-title":"Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity","volume":"15","author":"Shetty","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119321_bib70","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1158\/0008-5472.CAN-20-0242","article-title":"YAP Orchestrates Heterotypic Endothelial Cell Communication via HGF\/c-MET Signaling in Liver Tumorigenesis","volume":"80","author":"Thomann","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119321_bib71","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","article-title":"Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119321_bib72","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2026.119321_bib73","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119321_bib74","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119321_bib75","doi-asserted-by":"crossref","first-page":"39076","DOI":"10.1074\/jbc.M305101200","article-title":"Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway","volume":"278","author":"Yoo","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119321_bib76","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/cdd.2013.12","article-title":"p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway","volume":"20","author":"Farhang Ghahremani","year":"2013","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2026.119321_bib77","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154515","article-title":"\u03b2-Catenin signaling in hepatocellular carcinoma","volume":"132","author":"Xu","year":"2022","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2026.119321_bib78","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119321_bib79","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.biopha.2026.119321_bib80","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.biopha.2026.119321_bib81","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s12072-021-10184-9","article-title":"Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study","volume":"15","author":"Fu","year":"2021","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.biopha.2026.119321_bib82","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"IMbrave050 investigators, Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119321_bib83","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib84","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12916-025-04110-1","article-title":"Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial","volume":"23","author":"Shen","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.biopha.2026.119321_bib85","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119321_bib86","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/cas.15323","article-title":"Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system","volume":"113","author":"Maishi","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2026.119321_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70462","article-title":"Targeting Tumor Endothelial Cells by EGCG Using Specific Liposome Delivery System Inhibits Vascular Inflammation and Thrombosis","volume":"13","author":"Jia","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.biopha.2026.119321_bib88","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138808","article-title":"CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth","volume":"5","author":"Zhuang","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2026.119321_bib89","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2026.119321_bib90","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and Safety of IL13R\u03b12-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119321_bib91","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2026.119321_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715000","article-title":"Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13R\u03b12 and Suppress Malignant Glioma: A Preclinical Study","volume":"12","author":"Kim","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119321_bib93","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.omto.2022.01.002","article-title":"IL-13R\u03b12 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma","volume":"24","author":"Xu","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.biopha.2026.119321_bib94","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00262-023-03423-5","article-title":"IL13R\u03b12-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy","volume":"72","author":"Gu","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2026.119321_bib95","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152477","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"131","author":"Hegde","year":"2021","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2026.119321_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073780","article-title":"Targeting Interleukin-13 Receptor \u03b12 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy","volume":"25","author":"Kashyap","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119321_bib97","doi-asserted-by":"crossref","first-page":"42997","DOI":"10.18632\/oncotarget.17792","article-title":"IL13RA2 targeted alpha particle therapy against glioblastomas","volume":"8","author":"Sattiraju","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119321_bib98","doi-asserted-by":"crossref","first-page":"16589","DOI":"10.1038\/srep16589","article-title":"Improved anti-glioblastoma efficacy by IL-13R\u03b12 mediated copolymer nanoparticles loaded with paclitaxel","volume":"5","author":"Wang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119321_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020500","article-title":"Protein Tyrosine Phosphatase-1B Inhibition Disrupts IL13R\u03b12-Promoted Invasion and Metastasis in Cancer Cells","volume":"12","author":"Bartolom\u00e9","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119321_bib100","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41416-018-0259-7","article-title":"An IL13R\u03b12 peptide exhibits therapeutic activity against metastatic colorectal cancer","volume":"119","author":"Bartolom\u00e9","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119321_bib101","doi-asserted-by":"crossref","first-page":"30215","DOI":"10.1074\/jbc.M112.370015","article-title":"Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor \u03b12.","volume":"287","author":"Balyasnikova","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119321_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071731","article-title":"Inhibition of Liver Metastasis in Colorectal Cancer by Targeting IL-13\/IL13R\u03b12 Binding Site with Specific Monoclonal Antibodies","volume":"13","author":"Ja\u00e9n","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119321_bib103","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1958662","article-title":"Targeting and pharmacology of an anti-IL13R\u03b12 antibody and antibody-drug conjugate in a melanoma xenograft model","volume":"13","author":"Gupta","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.biopha.2026.119321_bib104","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1200\/JCO.2013.54.0526","volume":"32","author":"Pollack","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib105","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1245\/s10434-009-0900-z","article-title":"Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics","volume":"17","author":"Zeng","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib106","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-07-2131","article-title":"Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin","volume":"7","author":"Kioi","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119321_bib107","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/BF03401786","article-title":"Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer\/testis antigen","volume":"6","author":"Debinski","year":"2000","journal-title":"Mol. Med."},{"key":"10.1016\/j.biopha.2026.119321_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071388","article-title":"Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives","volume":"16","author":"De Gaetano","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119321_bib109","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119321_bib110","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119321_bib111","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2026.119321_bib112","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib113","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119321_bib114","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.cmet.2020.03.009","article-title":"Single-Cell RNA Sequencing Maps Endothelial Metabolic Plasticity in Pathological Angiogenesis","volume":"31","author":"Rohlenova","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2026.119321_bib115","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"IMbrave150 Investigators, Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2026.119321_bib116","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119321_bib117","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib118","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial","volume":"39","author":"Qin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib119","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"RESORCE Investigators, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119321_bib120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2026.119321_bib121","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib122","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119321_bib123","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib124","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib125","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-12-3214","article-title":"Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study","volume":"19","author":"Shibata","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119321_bib126","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119321_bib127","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2021.4978","article-title":"IL13R\u03b12- and EGFR-targeted pseudomonas exotoxin potentiates the TRAIL-mediated death of GBM cells","volume":"48","author":"Karaka\u015f","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2026.119321_bib128","first-page":"6194","article-title":"Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer","volume":"61","author":"Kawakami","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119321_bib129","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/cam4.449","article-title":"Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma","volume":"4","author":"Liu-Chittenden","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.biopha.2026.119321_bib130","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1078-0432.CCR-09-2015","article-title":"Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy","volume":"16","author":"Shimamura","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119321_bib131","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1158\/1078-0432.CCR-07-0938","article-title":"A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer","volume":"13","author":"Stish","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119321_bib132","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3109\/14653249.2012.666633","article-title":"Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor \u03b12 chain in recurrent malignant glioma patients with HLA-A*24\/A*02 allele","volume":"14","author":"Iwami","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biopha.2026.119321_bib133","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1479-5876-8-116","article-title":"Interleukin-13 receptor \u03b12 DNA prime boost vaccine induces tumor immunity in murine tumor models","volume":"8","author":"Nakashima","year":"2010","journal-title":"J. Transl. Med"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:40:08Z","timestamp":1779244808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226003549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":133,"alternative-id":["S0753332226003549"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119321","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-13R\u03b12 in liver cancer: Endothelial target for precision therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119321"}}